Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2012

Tsimberidou Apostolia-Maria, Iskander Nancy G, Hong David S, Wheler Jennifer J, Falchook Gerald S, Fu Siqing, Piha-Paul Sarina, Naing Aung, Janku Filip, Luthra Rajyalakshmi, Ye Yang, Wen Sijin, Berry Donald, Kurzrock Razelle

Abstract excerpt

PURPOSE: We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations. PATIENT AND METHODS: Patients with advanced cancer were treated in the Clinical Center for Targeted Therapy. Molecular analysis was conducted in the MD Anderson Clinical Laboratory Improvement Amendments (CLIA)-certified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Genes, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Liver Neoplasms

Share to Molecular Targeted Therapy

Share to Multivariate Analysis

Share to Precision Medicine

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 22966018
DOI: 10.1158/1078-0432.CCR-12-1627
PMCID: PMC4454458

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.PMID 22966018Read ↗

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.Semantic proximity Read ↗

A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer.Semantic proximity Read ↗

Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University ExperienceSemantic proximity Read ↗

Molecular Tumor Board: The University of California San Diego Moores Cancer Center ExperienceSemantic proximity Read ↗

Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.Semantic proximity Read ↗

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II TrialSemantic proximity Read ↗

Application of molecular profiling in clinical trials for advanced metastatic cancers.Semantic proximity Read ↗

Targeted Therapy Improves Real-World Survival in Patients with Molecularly Matched Advanced Biliary Tract CancerSemantic proximity Read ↗

Personalized therapies in the cancer "omics" eraSemantic proximity Read ↗

Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.Semantic proximity Read ↗

Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.Semantic proximity Read ↗

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 TrialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.